Craneware (CRW) Stock Rating Reaffirmed by Peel Hunt

Craneware (LON:CRW)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a note issued to investors on Monday, February 4th.

Separately, Berenberg Bank initiated coverage on shares of Craneware in a research report on Thursday, November 15th. They set a “buy” rating and a GBX 3,600 ($47.04) price objective for the company.

Shares of LON:CRW traded up GBX 15 ($0.20) during midday trading on Monday, hitting GBX 2,655 ($34.69). The stock had a trading volume of 4,810 shares, compared to its average volume of 14,260. Craneware has a fifty-two week low of GBX 1,170 ($15.29) and a fifty-two week high of GBX 2,040 ($26.66).

Craneware Company Profile

Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company offers patient engagement solutions, such as InSight Medical Necessity, a software-as-a-service (SaaS) solution that provides medical necessity validation for United States payers and advance beneficiary notice creation; and Trisus Patient Payment, which provides hospitals and health systems to modernize patient payment.

Recommended Story: Conference Calls

Receive News & Ratings for Craneware Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Craneware and related companies with's FREE daily email newsletter.